imatinib mesylate (LKT Laboratories)

LKT Laboratories is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

LKT Laboratories imatinib mesylate

Experimental and analytical protocol used in the study. Experimental series 1 was undertaken to estimate the differential gene expression in 48,803 probes upon treatment with <t>imatinib</t> or omacetaxine. For these experiments both drugs were administered at a dose of IC20. Experimental series 2 was undertaken to measure an individual’s sensitivity to drug response (SDR) which was estimated as the slope of the regression line (arrows) between log of dose administered and cell viability. Data from these experiments were also used to estimate the IC20 values used in Experimental Series 1. Differential gene expression (iFC and oFC) was tested for statistical significance for departure from zero as well as for association with the corresponding SDR as shown. Details of the statistical methods mentioned in the figure are provided in the text.

Imatinib Mesylate, supplied by LKT Laboratories, used in various techniques. Bioz Stars score: 93/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/infinium+methylation+microarray+platform/Imatinib+Mesylate/pmc03483163-88-0-2
Average 93 stars, based on 16 article reviews

imatinib mesylate - by Bioz Stars, 2026-09

93/100 stars

Images

1) Product Images from "Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines"

Article Title: Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

Journal: BMC Medical Genomics

doi: 10.1186/1755-8794-5-37

Figure Legend Snippet: Experimental and analytical protocol used in the study. Experimental series 1 was undertaken to estimate the differential gene expression in 48,803 probes upon treatment with imatinib or omacetaxine. For these experiments both drugs were administered at a dose of IC20. Experimental series 2 was undertaken to measure an individual’s sensitivity to drug response (SDR) which was estimated as the slope of the regression line (arrows) between log of dose administered and cell viability. Data from these experiments were also used to estimate the IC20 values used in Experimental Series 1. Differential gene expression (iFC and oFC) was tested for statistical significance for departure from zero as well as for association with the corresponding SDR as shown. Details of the statistical methods mentioned in the figure are provided in the text.

Techniques Used: Gene Expression

Figure Legend Snippet: Heritability of the inhibitory concentration of experimental drugs

Techniques Used: Concentration Assay

Differential gene expression response upon treatment with imatinib or omacetaxine. (A-B) Volcano plots depicting the extent (x-axis) and significance (y-axis) of differential gene expression for each probe set (n = 48,803) after treatment with either imatinib (A) or omacetaxine (B). (C) Results of k-means clustering of the statistically significant probes based on their differential gene expression in response to imatinib (x-axis) or omacetaxine (y-axis) treatment. The color codes for each cluster are indicated in the index, clusters have been referenced consistently throughout the manuscript. The lack of data towards the center of the scatter plot is due to probes that were not significant (in response to either imatinib or omacetaxine treatment), which are not shown in this figure. (D) Point estimates and 95% confidence ellipses for the association of differential gene expression with sensitivity of drug response (SDR). Plotted in this chart are the regression coefficients from the polygenic models (equation (2)) for the set of probes belonging to the color-coded clusters identified in panel C. (E) Heritability of differential gene expression. The data are shown separately for probe sets belonging to each cluster identified in panel C. Pie charts at the top demonstrate the proportion of probe sets within the corresponding cluster that showed a heritability value exceeding zero for differential gene expression in response to imatinib as well as omacetaxine. The bar charts show the mean heritability of imatinib (blue) and omacetaxine (red) response for genes within each cluster. For reference, color-coded background is shown on the chart corresponding to the clusters. Within each cluster, the difference in the mean heritability for imatinib and omacetaxine response was assessed using a paired Student’s t test, the result of which is shown as the p-value at the top of the bars. ih2r, heritability of differential gene expression in response to imatinib; oh2r, heritability of differential gene expression in response to omacetaxine.

Figure Legend Snippet: Differential gene expression response upon treatment with imatinib or omacetaxine. (A-B) Volcano plots depicting the extent (x-axis) and significance (y-axis) of differential gene expression for each probe set (n = 48,803) after treatment with either imatinib (A) or omacetaxine (B). (C) Results of k-means clustering of the statistically significant probes based on their differential gene expression in response to imatinib (x-axis) or omacetaxine (y-axis) treatment. The color codes for each cluster are indicated in the index, clusters have been referenced consistently throughout the manuscript. The lack of data towards the center of the scatter plot is due to probes that were not significant (in response to either imatinib or omacetaxine treatment), which are not shown in this figure. (D) Point estimates and 95% confidence ellipses for the association of differential gene expression with sensitivity of drug response (SDR). Plotted in this chart are the regression coefficients from the polygenic models (equation (2)) for the set of probes belonging to the color-coded clusters identified in panel C. (E) Heritability of differential gene expression. The data are shown separately for probe sets belonging to each cluster identified in panel C. Pie charts at the top demonstrate the proportion of probe sets within the corresponding cluster that showed a heritability value exceeding zero for differential gene expression in response to imatinib as well as omacetaxine. The bar charts show the mean heritability of imatinib (blue) and omacetaxine (red) response for genes within each cluster. For reference, color-coded background is shown on the chart corresponding to the clusters. Within each cluster, the difference in the mean heritability for imatinib and omacetaxine response was assessed using a paired Student’s t test, the result of which is shown as the p-value at the top of the bars. ih2r, heritability of differential gene expression in response to imatinib; oh2r, heritability of differential gene expression in response to omacetaxine.

Techniques Used: Gene Expression

Validation of the microarray results by qPCR. (A) Scatter plot of the differential gene expression in response to imatinib (blue) and omacetaxine (red). Both axes show log-transformed differential gene expression. Results are for all five genes that were assayed by microarray and qPCR. Since qPCR used HPRT1 as the normalizer gene, the microarray based results are shown after correction for HPRT1 expression. (B) Mean differential gene expression for the five selected genes by qPCR (left panel) and microarray (right panel) in response to imatinib (blue bars) and omacetaxine (red bars) treatment. The bars represent log-transformed differential gene expression values.

Figure Legend Snippet: Validation of the microarray results by qPCR. (A) Scatter plot of the differential gene expression in response to imatinib (blue) and omacetaxine (red). Both axes show log-transformed differential gene expression. Results are for all five genes that were assayed by microarray and qPCR. Since qPCR used HPRT1 as the normalizer gene, the microarray based results are shown after correction for HPRT1 expression. (B) Mean differential gene expression for the five selected genes by qPCR (left panel) and microarray (right panel) in response to imatinib (blue bars) and omacetaxine (red bars) treatment. The bars represent log-transformed differential gene expression values.

Techniques Used: Biomarker Discovery, Microarray, Gene Expression, Transformation Assay, Expressing

other:

Article Title: Total gastrectomy may result in reduced drug effectiveness due to an increase in the expression of the drug-metabolizing enzyme Cytochrome P450, in the liver.
Article Snippet: 0928-0987/$ see front matter 2013 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.ejps.2013.09.017 ⇑ Corresponding author.. Address: Department of Clinical Pharmacokinetics, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan.. Tel.

Article Title: Development of a specific and sensitive enzyme-linked immunosorbent assay for the quantification of imatinib.
Article Snippet: Reagents Imatinib mesylate was obtained from LKT Lab- * To whom correspondence should be addressed. e-mail: sait1102@life.sojo-u.ac.jp The authors declare no conflict of interest. oratories, Inc. (St. Paul, MN, U.S.A.).

Chromatography:

Article Title: High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction
Article Snippet: Afatinib was purchased from Toronto Research Chemicals (Toronto, Canada). .. Imatinib mesylate for use as the internal standard (IS) was purchased from LKT Laboratories (St. Louis, MO, USA). tert-Butyl methyl ether (TBME), ammonium formate, formic acid, and liquid chromatography–mass spectrometry (LC-MS)-grade acetonitrile were purchased from Wako (Osaka, Japan). ..

Activity Assay:

Article Title: TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1
Article Snippet: .. To analyze the role of ABL1 activity, the ABL inhibitors imatinib mesylate (LKT Laboratories Inc.) and ponatinib (APExBIO) were used at the indicated concentrations for 24 hours. .. siRNAs were transfected into cells using INTERFERin transfection reagent (Polyplus-transfection) at concentrations of 10 nM or otherwise indicated; after 48 hours of transfection, the knockdown efficiency was evaluated by determining the protein levels in whole-cell lysates.

Mouse Assay:

Article Title: c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
Article Snippet: They were pre-treated with a single i.p. injection of benserazide (12.5 mg/kg; Sigma–Aldrich) dissolved in 0.9% saline 20 min before administration of levodopa or saline. .. Mice received a single i.p. injection of imatinib mesylate (10 or 25 mg/kg; LKT Laboratories, St. Paul, MN, United States) dissolved in 0.9% saline containing 10% dimethyl sulfoxide 3 days after the administration of MPTP or saline. ..

Injection:

Saline:

Concentration Assay:

Article Title: GENETIC BASIS FOR THE INCREASED EXPRESSION OF VACUOLAR H+ TRANSLOCATING ATPASE GENES UPON IMATINIB TREATMENT IN HUMAN LYMPHOBLASTOID CELLS
Article Snippet: Cells were maintained, as previously described, 11 in complete RPMI 1640 medium (Life Technologies, Grand Island, NY) at 37°C and 5% CO 2 . .. Imatinib mesylate (LKT Laboratories, St Paul, MN) was solubilized in water at 10mM concentration, and stored at −20°C. ..

Review